Mályvavirág Foundation and BioTechUSA for prehabilitation

By: Trademagazin Date: 2024. 04. 02. 11:45

🎧 Hallgasd a cikket: Nyelv: Sebesség: 1.05×

In the spring, Mályvavirág Foundation will launch a 2-year prehabilitation pilot project called NOPREM for nearly 400 people, the aim of which is to improve the quality of life of women undergoing surgery due to gynecological cancer. As the first supporter of the BioTechUSA group’s social responsibility program, the unique initiative in Hungary was supported by the purchase of an Inbody body composition analysis machine and self-produced protein and vitamin D preparations for a total value of HUF 8 million. The support was given by the world fitness champion Virág Kiss, the charitable brand ambassador of BioTechUSA.

More than 1,000 new diseases per year

After breast cancer, cervical cancer is the second most common malignancy among women under 45 years of age in Europe. In Hungary, about 1,500 women are told by their doctor that they have cervical cancer every year, and because of this, we lose more than 400 women every year. Cervical cancer is caused by the human papillomavirus, i.e. the HPV virus. Its development could be prevented in most cases, because one examination per year is enough to detect the disease in time. In addition, vaccination can now be requested, which provides approximately 60-70% protection.

Uterine cancer starts from the mucous membrane of the uterus, its cancerous change. It is the second most common gynecological malignancy. It cannot be screened, because the cytological examination only screens for cervical cancer. It is the most curable of all gynecological tumors, as it can be detected at an early stage. Since uterine cancer is usually a disease of older women, the average age of women with uterine cancer is over 60 years, and it rarely occurs in younger women.